Combination therapy with MEK inhibitors for the treatment of cancer

PCT/EP2024/065522Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. It is a large subset of diseases characterized by the uncontrollable growth of abnormal cells. The mitogen-activated protein kinase (MAPK) cascade is an intracellular signaling pathway involved in the regulation of cellular proliferation and the survival of tumor cells. Several different mutations involving BRAF (v-raf murine sarcoma viral oncogene homolog B1) or NRAS (neuroblastoma RAS viral oncogene homolog) exert an oncogenic effect by activating the MAPK pathway. MEK is downstream of BRAF in the MAPK signaling pathway. Since mutations in both NRAS and BRAF signal through MEK, inhibition of MEK has proven to be an attractive therapeutic strategy for cancers carrying BRAF and NRAS activating mutations. The present invention relates to the field of cancer and, more particularly, to a combination comprising mitogen-activated protein kinase kinase (MEK) inhibitors and Omomyc and its use in medicine, more particularly in the prevention and/or treatment of cancer.